NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical
by Zacks Equity Research
NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.
NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down
by Zacks Equity Research
NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.
NuVasive (NUVA) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of -40.74% and -7.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Reports Next Week: What Awaits?
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive (NUVA) Announces Two Developments in Cohere TLIF Line
by Zacks Equity Research
According to NuVasive (NUVA), Porous PEEK is a clear differentiator for the company in the market.
NuVasive (NUVA) Expands Training Opportunities With New Center
by Zacks Equity Research
NuVasive's (NUVA) East Coast Experience Center reflects the company's commitment to provide best quality surgeon education and training to enhance the standard of patient care in spine surgery.
5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space
by Debanjana Dey
OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.
NuVasive (NUVA) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
NuVasive (NUVA) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.
NuVasive (NUVA) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 39.54% and 3.03%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Launches Modulus ALIF for Anterior Spine Surgery
by Zacks Equity Research
The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.
NuVasive (NUVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes
by Zacks Equity Research
We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.
Why Is NuVasive (NUVA) Down 5.2% Since Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.
NuVasive (NUVA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 12.12% and 3.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Enters Overbought Territory
by Zacks Equity Research
NuVasive (NUVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus
by Debanjana Dey
Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.
NuVasive's (NUVA) Simply Cervical Artificial Disc Gets FDA Nod
by Zacks Equity Research
NuVasive's (NUVA) Simplify Disc demonstrated an overall clinical success rate nearly 10% higher than the anterior cervical discectomy and fusion.
Why Is NuVasive (NUVA) Up 15.4% Since Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive (NUVA) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
NuVasive (NUVA) is optimistic about its strong international performance and a huge growth potential in the spine market.
NuVasive (NUVA), ISSGF Expand Tie-Up With Launch of 2 Studies
by Zacks Equity Research
NuVasive (NUVA) extends its long-term partnership with ISSGF and initiates additional clinical studies to transform the future of spine care.
NuVasive (NUVA) Enters Overbought Territory
by Zacks Equity Research
NuVasive (NUVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company